This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection (SCORPIO-PEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05897541
Recruitment Status : Recruiting
First Posted : June 9, 2023
Last Update Posted : April 2, 2024
Sponsor:
Information provided by (Responsible Party):
Shionogi Inc. ( Shionogi )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Infection Drug: S-217622 Drug: Placebo Phase 3

Detailed Description:
This study will enroll 2 types of participants: 1. those with a negative screening SARS-CoV-2 infection (referred to as "study participants"); 2. those with a positive screening SARS-CoV-2-infection (referred to as "index participants"). Study participants will receive study intervention (S-217622 or placebo), index participants will receive no study intervention.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of S-217622 in the Prevention of Symptomatic SARS-CoV-2 Infection in Household Contacts of an Individual With Symptomatic COVID-19
Actual Study Start Date : June 9, 2023
Estimated Primary Completion Date : September 30, 2024
Estimated Study Completion Date : September 30, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: S-217622
S-217622 will be administered orally for 5 days.
 Drug: S-217622
Administered as a tablet.
Placebo Comparator: Placebo
Placebo matching to S-217622 will be administered orally for 5 days.
 Drug: Placebo
Administered as a tablet.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Participants in the Modified Intention-to-treat (mITT) Population with a Negative Screening SARS-CoV-2 Infection who are Infected with SARS-CoV-2 and Have COVID-19 Symptoms Onset [ Time Frame: Day 1 through Day 10 ]

Secondary Outcome Measures :
  1. Number of Participants in the Intention-to-treat (ITT) Population with a Negative Screening SARS-CoV-2 Infection who are Infected with SARS-CoV-2 and Have COVID-19 Symptoms Onset [ Time Frame: Day 1 through Day 10 ]
  2. Number of Participants Infected with SARS-CoV-2 Regardless of Occurrence of COVID-19 Symptoms [ Time Frame: Day 1 through Days 10, 15, or 28 ]
  3. Time to the First Positive RT-PCR Result [ Time Frame: Day 1 through Day 10 ]
  4. Number of Participants with a Positive RT-PCR Result [ Time Frame: Day 1 through Day 10 ]
  5. Number of Participants Infected with SARS-CoV-2 with no COVID-19 Symptoms [ Time Frame: Day 1 through Day 10 ]
  6. Number of Participants with Sustained Resolution of all COVID-19 Symptoms [ Time Frame: Day 1 through Day 28 ]
  7. Number of Participants with Sustained Resolution of Each COVID-19 Symptom [ Time Frame: Day 1 through Day 28 ]
  8. Change in Total Score of COVID-19 Symptoms [ Time Frame: Day 1 through Day 10 ]
  9. Time From First Confirmed SARS-CoV-2 Until at Least 1 COVID-19 Symptom [ Time Frame: Day 1 through Day 28 ]
  10. Time From First Confirmed SARS-CoV-2 Until COVID-19 Symptoms Onset [ Time Frame: Day 1 through Day 28 ]
  11. Number of Participants Experiencing Hospitalization or Death from Any Cause [ Time Frame: Day 1 through Day 28 ]
  12. Plasma Concentration of S-217622 [ Time Frame: Day 3, Day 6, and Event Driven ]
  13. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Day 1 through Day 28 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Index Participants

Only 1 index participant from each household will be enrolled in the study. Participants are eligible to be included as an index participant if all of the following criteria apply:

  1. Pediatric participants or adult participants (of any age)

  2. The index participant must:

    1. Have at least 1 COVID-19 symptom within 24 hours before the index participant providing informed consent. COVID-19 symptom(s) must be deemed by the investigator as related to the current SARS-CoV-2 infection (not related to preexisting comorbidities) or deemed as preexisting and worsened due to SARS-CoV-2 infection.
    2. Must have positive SARS-CoV-2 test (a nucleic acid amplification test or antigen test) from any respiratory tract specimen from a sample collected prior to randomization of the participant
  3. Must have a potential study participant who can participate in the study after onset of COVID-19 symptoms in an index participant

Study Participants

Multiple study participants from the same household are allowed to be enrolled in the study. The study intervention randomization will be performed based at the study participant's level. Participants will be eligible to be included in the study only if all of the following criteria apply:

  1. ≥ 12 years of age at the time of signing the informed consent
  2. Has a negative screening for SARS-CoV-2 infection, as determined by SARS-CoV-2 test (a nucleic acid amplification test or antigen test) from any respiratory tract specimen (for example, oropharyngeal, nasopharyngeal or nasal swab, or saliva).
  3. Has lived in household with index participant and will continue to live in same household and share common areas such as dining rooms and bathrooms until the end of the study

  4. Must not be considered by the investigator or subinvestigator to have SARS-CoV-2 infection and:

    1. No measured fever at Screening (defined as body temperature ≥ 38.0°Celsius [C] per tympanic or rectal thermometer or ≥ 37.5°C per axillary, oral, or forehead/temporal thermometer)
    2. No COVID-19 symptoms at Screening (if a participant has COVID-19-like symptoms caused by comorbidities, only 1 symptom will be allowed)
  5. Capable and willing to complete a participant diary

  6. a. Male participants: Participants with partners that are woman of childbearing potential (WOCBP) must agree to use effective contraception. Participants with pregnant partners must agree to use effective contraception.

    b. Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and the following conditions applies:

    • Is not a WOCBP or

    • All of the following apply:

      • Is a WOCBP and using a contraceptive method that is effective as described in the protocol.
      • A WOCBP must have a negative urine pregnancy test within 24 hours before the first dose of study intervention period.
      • If a urine pregnancy test cannot be confirmed as negative (for example, an ambiguous result), a serum pregnancy test must be negative.
    • Additional requirements for pregnancy testing during and after study intervention as described in the protocol.
    • The investigator/subinvestigator will review medical history, menstrual history, and recent sexual activity to decrease the risk of inclusion of a woman with an early undetected pregnancy.
  7. Participant must be randomized ≤ 72 hours from onset of COVID-19 symptoms in the index participant.

Exclusion Criteria:

Study Participants: Participants will be excluded from the study if any of the following criteria apply:

  1. Tested positive for SARS-CoV-2 in the past 6 months.
  2. Have an underlying disease requiring systemic corticosteroids (excluding topical), antipyretics/analgesics, or immunosuppressive agents.
  3. Known current renal impairment defined as creatinine clearance < 30 milliliters/minute by Cockcroft Gault or requiring dialysis.
  4. Participants with severe liver dysfunction, such as known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy).
  5. Received approved, authorized, or investigational convalescent plasma, or other anti- SARS-CoV-2 biologic products within 3 months of the Screening Visit
  6. Received approved, authorized, or investigational anti-SARS-CoV-2 monoclonal antibodies (mAbs) in the last 6 months.
  7. Received any SARS-CoV-2 vaccine within 6 months prior to the Screening Visit or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments until the end of the study.

  8. Participants who have used any of the following drugs within 14 days prior to enrollment:

    1. Strong cytochrome P450 (CYP) 3A inducer
    2. Products containing St. John's wort
  9. Exposed to an investigational drug within 30 days or 5 half-lives of the drug prior to the Screening Visit.
  10. Positive urine pregnancy test at Screening Visit or are lactating.
  11. Known allergy/sensitivity or any hypersensitivity to components of S-217622 or placebo for S-217622.
  12. Any condition or circumstance that, in the opinion of the investigator or subinvestigator, would compromise the safety of the participant or the quality of the study data.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05897541


Contacts
Layout table for location contacts
Contact: Shionogi Clinical Trials Administrator Clinical Support Help Line 1-800-849-9707 Shionogiclintrials-admin@shionogi.co.jp

Locations
Show Show 98 study locations
Sponsors and Collaborators
Shionogi
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Shionogi
ClinicalTrials.gov Identifier: NCT05897541    
Other Study ID Numbers: 2206T1331
2022-002898-28 ( EudraCT Number )
2023-503200-91-00 ( Other Identifier: Clinical Trials Information System (CTIS) )
First Posted: June 9, 2023    Key Record Dates
Last Update Posted: April 2, 2024
Last Verified: March 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
COVID-19
Disease Attributes
Pathologic Processes
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
 Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases